The deal has the backing of the three largest shareholders, and Novavax expects to close the takeover by the end of next month. With the deal, Novavax gets ownership of a proprietary adjuvant technology it can use in vaccine candidates for pandemic flu, rabies, respiratory syncytial virus in the elderly, foot-and-mouth and other diseases.
Fraunhofer Center for Molecular Biotechnology could receive up to $9.9 million in funding from NIH's National Institute of Allergy and Infectious Diseases to develop the next generation of anthrax vaccines.
Isconova has purchased the Danish drug delivery and adjuvants company Nordic Vaccine for over 4 million Swedish kroner, or $663,000. "The acquisition of Nordic Vaccine is in line with Isconova's
Sweden's Isconova has secured financing of 30 million Swedish kronor ($5.2 million) from InnovationsKapital for its work in vaccine adjuvant technology.